Cost of CGMs, Insulin, and Diabetes Supplies in 2026: What You'll Actually Pay

How Much Does a CGM Cost Without Insurance?

CGM costs without insurance range from roughly $99 to $400 per month, depending on the specific device and how many sensors you need. Dexcom G7 three-packs list at approximately $129 to $149 through pharmacies, and each sensor lasts 10 days, meaning you'll spend roughly $390 to $450 per month at full cash price. Abbott's FreeStyle Libre 3, which runs for 14 days per sensor, typically costs $75 to $85 per two-sensor pack, landing at about $135 to $170 monthly.

The FDA cleared Dexcom Stelo in 2024 as an over-the-counter CGM for adults without insulin dependence. Stelo sells for approximately $99 for a 30-day supply, no prescription required, which meaningfully expands access for people managing prediabetes or type 2 diabetes on oral agents alone. Abbott followed with Lingo and Libre Rio, also OTC-designated, in the same price range.

For patients who use insulin and meet Medicare criteria, CGMs classified as therapeutic devices receive coverage under Medicare Part B as durable medical equipment, reducing out-of-pocket costs to the standard 20 percent coinsurance after deductible. A 2023 analysis in JAMA Internal Medicine found that Medicare beneficiaries with continuous glucose monitoring had significantly lower rates of severe hypoglycemia-related emergency visits compared with those using intermittent self-monitoring, reinforcing coverage rationale.

Commercially insured patients often pay $0 to $60 per month when CGMs are covered as a pharmacy or durable medical equipment benefit, though prior authorization is almost universal for branded devices. Manufacturer copay cards can offset commercial cost-sharing to $0 for patients who qualify.

What Is the Actual Cost of Insulin in 2026?

Insulin list prices remain high, but the gap between list price and actual patient cost has narrowed significantly since 2023 through a combination of legislative caps, manufacturer programs, and generic market entry. The three major rapid-acting analogues, insulin lispro (generic Humalog), insulin aspart (generic NovoLog), and insulin glulisine, now have biosimilar or authorized generic versions available at dramatically lower prices than their branded counterparts.

Branded Humalog (insulin lispro, 100 units/mL) carries a list price near $274 per vial. The FDA-approved authorized generic version sells for roughly $35 per vial through GoodRx at major pharmacy chains, a reduction of nearly 87 percent. Insulin aspart generics follow a similar pattern, with cash prices as low as $49 to $72 per vial depending on pharmacy and discount applied.

For long-acting insulin, Lantus (insulin glargine) biosimilars including Basaglar, Semglee, and Rezvoglar have pushed prices down to $98 to $150 per vial cash, compared with Lantus list prices above $300. The FDA biosimilar approval pathway has accelerated market entry of interchangeable insulin products, meaning pharmacists can substitute without a new prescription in states that allow it.

A 2021 analysis published in JAMA documented that 14.1 percent of insulin-dependent patients in the United States reported insulin underuse due to cost in the prior 12 months, a figure that has likely shifted downward following the IRA cap and generic expansion. Even so, patients without Medicare or employer coverage still face substantial barriers.

How Does the Inflation Reduction Act Insulin Cap Work?

The Inflation Reduction Act (IRA) capped Medicare Part D cost-sharing for insulin at $35 per month per covered product, effective January 1, 2023. The $35 cap applies at each fill regardless of the insulin's list price or the patient's deductible stage. CMS confirmed this benefit in its Part D guidance, and it covers all insulin products on a plan's formulary.

The cap does not extend to private insurance, employer plans, or the uninsured. Congress attempted to include a $35 private-insurance cap in the IRA but that provision failed the Senate's Byrd rule. Patients on commercial plans are subject to whatever cost-sharing their specific plan applies, which can reach $50 to $150 per fill for branded products.

Under IRA rules effective in 2025, Medicare Part D's redesign also introduced a $2,000 annual out-of-pocket cap for all Part D drugs. That structural change benefits patients on expensive diabetes regimens beyond just insulin. The Kaiser Family Foundation analysis of Part D restructuring estimated roughly 1.4 million Part D enrollees will reach the $2,000 cap annually.

The American Diabetes Association's 2024 Standards of Care state directly: "The cost of insulin is a significant barrier to adherence, and clinicians should be aware of lower-cost insulin options and patient assistance resources." (ADA Standards of Medical Care in Diabetes, 2024)

What Manufacturer Patient-Assistance Programs Are Available?

All three major insulin manufacturers, Eli Lilly, Novo Nordisk, and Sanofi, operate patient-assistance programs (PAPs) that can provide insulin at $0 or near $0 for uninsured or underinsured patients who meet income thresholds.

Eli Lilly: The Lilly Insulin Value Program caps all Lilly insulins (Humalog, Basaglar, Humulin) at $35 per month for patients regardless of insurance status. Separately, Lilly Cares Foundation provides free insulin to uninsured patients earning up to 400 percent of the federal poverty level ($58,320 for a single adult in 2024). Lilly's 2023 announcement cut the list price of Humalog by 70 percent and expanded the $35 monthly cap program permanently.

Novo Nordisk: The Novo Nordisk Patient Assistance Program supplies NovoLog, Levemir, Tresiba, and Victoza at no cost to uninsured or underinsured patients below 400 percent of FPL. The NovoCare program also offers a $99 monthly supply of NovoLog FlexPen for cash-paying patients.

Sanofi: The Insulins Valyou Savings Program caps Lantus, Toujeo, Apidra, and Admelog at $99 per month for uninsured patients, with additional $0 programs for patients below 250 percent FPL through the Sanofi Patient Connection program.

Abbott CGM assistance: Abbott's myFreeStyle program offers a free 14-day FreeStyle Libre 3 starter kit to new users. Dexcom's ACCESS program provides G7 sensors at reduced or no cost to patients meeting income and insurance criteria.

A 2022 Health Affairs study found that even with existing PAPs, 29 percent of eligible low-income insulin users were not enrolled, primarily because of application complexity and lack of physician referral. That gap represents a direct clinical opportunity.

How Do GoodRx and Generic Insulin Cut Costs?

GoodRx and similar discount platforms negotiate pricing through pharmacy benefit intermediaries and can dramatically reduce cash prices for insulin, particularly generic and authorized-generic versions. These discounts apply at the point of sale and do not require insurance.

At CVS, Walgreens, and Walmart using GoodRx, insulin lispro injection (generic Humalog) 100 units/mL 10 mL vial may price as low as $35 to $55. Insulin aspart (generic NovoLog) runs $49 to $72. These prices represent roughly a 70 to 87 percent reduction from branded list prices. GoodRx health data published in 2023 tracked average insulin prices and confirmed substantial variation by pharmacy, with independent pharmacies sometimes pricing higher than large chains for the same product.

Walmart sells Novolin R (regular human insulin), Novolin N (NPH), and Novolin 70/30 over the counter in most states at approximately $25 per vial, no prescription needed. These are older human insulin formulations rather than modern analogs. The ADA's position statement on insulin access notes that while human insulin is a lower-cost option, analog insulins provide pharmacokinetic advantages for many patients, and cost should not be the sole factor in insulin selection.

Mark Cuban's Cost Plus Drugs platform lists several generic medications relevant to diabetes management, including metformin at $5 for 90 tablets. Insulin products are not yet available through Cost Plus as of early 2026, but the platform's entry into the space continues to pressure pharmacy pricing broadly. Cost Plus Drugs pricing methodology is published openly and uses a manufacturer cost-plus-15 percent model.

Patients combining a GoodRx discount with a manufacturer's PAP enrollment cannot use both simultaneously at the pharmacy counter, a common source of confusion. The standard approach is to compare both options and apply the one yielding the lower cost at each fill.

CGM Cost Comparison: Dexcom G7 vs. FreeStyle Libre 3 vs. Stelo

Selecting a CGM based on cost requires comparing sensor duration, warmup time, accuracy (MARD), and insurance coverage, not just sticker price. The table below reflects 2026 cash prices at major US pharmacies.

| Device | Sensor Duration | Cash Price/Month (approx.) | Prescription Required | MARD | |---|---|---|---|---| | Dexcom G7 | 10 days | $390, $450 | Yes (Rx) | 8.2% | | FreeStyle Libre 3 | 14 days | $135, $170 | Yes (Rx) | 7.9% | | Dexcom Stelo | 15 days | ~$99 | No (OTC) | 8.8% | | Abbott Lingo | 14 days | ~$89 | No (OTC) | not yet independently validated |

MARD figures for Dexcom G7 and FreeStyle Libre 3 come from key trial data reported in peer-reviewed literature. The G7 MARD of 8.2 percent was reported in the Dexcom G7 key trial published in Diabetes Technology and Therapeutics. FreeStyle Libre 3's 7.9 percent MARD appeared in the CONFIRM study (N=312), a prospective accuracy evaluation published in Diabetes Care.

For patients on insulin, both G7 and Libre 3 meet FDA criteria for therapeutic CGM use, supporting dosing decisions without a confirmatory fingerstick (except when symptoms don't match sensor readings). Stelo is cleared for non-insulin-using adults; it does not display urgent low glucose alerts and is not labeled for dosing decisions.

Does Insurance Cover CGMs, and What Determines Coverage?

Private insurance coverage of CGMs expanded considerably between 2020 and 2026 but remains inconsistent. Coverage depends on the payer, the patient's diagnosis, insulin-use status, and whether the CGM is classified as durable medical equipment (DME) or a pharmacy benefit, as those two pathways carry different cost-sharing structures.

Under Medicare Part B, therapeutic CGMs are covered as DME for beneficiaries who use insulin (any type) or have a history of problematic hypoglycemia. Coverage requires a treating physician's order and documentation of insulin use. The patient pays 20 percent coinsurance after the Part B deductible ($240 in 2024).

Most commercial insurers follow similar criteria but add prior-authorization requirements. A 2022 analysis in Diabetes Care documented that CGM use varied 3.5-fold across racial and income groups, with Black and Hispanic patients and those in lower-income quintiles significantly less likely to have a CGM despite similar insulin-use rates. The authors attributed this disparity partly to differential insurance access and partly to prescriber-level differences in who gets offered a device.

For type 2 patients on oral agents only, CGM coverage is inconsistently applied. Several major payers cover CGMs for type 2 patients not on insulin as of 2025, but it typically requires documentation of hypoglycemia risk or specific A1C criteria above 8.0 percent. A clinician's letter of medical necessity improves approval rates substantially.

What Are the Real Total Costs of Managing Diabetes Per Year?

The American Diabetes Association reported in its 2023 economic analysis that the average annual medical expenditure for a person with diabetes was $19,736, compared with $6,167 for a person without diabetes, a ratio of approximately 2.3 times higher. (ADA, Economic Costs of Diabetes in the U.S. in 2022) Insulin and supplies account for a significant share of that gap.

Broken down by supply category, a type 1 patient using a CGM, insulin pump, and analog insulin might face these annual cash costs without insurance:

• CGM sensors (FreeStyle Libre 3): $1,620, $2,040
• Insulin pump consumables (Omnipod 5 pods): approximately $3,000, $4,500
• Rapid-acting insulin analog (branded): $3,000, $5,500
• Long-acting insulin analog (branded): $2,400, $4,000

Substituting generic insulin and using manufacturer programs can reduce the insulin line by 70 to 90 percent. A patient on the Lilly $35/month cap for Humalog plus Basaglar pays $840 per year for both insulins combined, versus a potential $7,000 to $9,500 at branded list price. That difference, over $6,000 annually, reflects why knowing program eligibility is a clinical responsibility, not just a financial one.

The CDC's National Diabetes Statistics Report 2024 estimated 38.4 million Americans have diabetes, and 8.7 million use insulin. Even a modest reduction in average insulin cost-sharing per patient produces aggregate savings in the billions.

How to Access the Lowest Possible Price: A Step-by-Step Approach

Start with insurance status. Patients with Medicare Part D pay no more than $35 per month per insulin product under the IRA cap. Patients with commercial insurance should verify their plan's formulary tier for the specific insulin and request the lowest-cost formulary alternative from their prescriber if the preferred product is Tier 3 or higher.

For uninsured patients, apply to the relevant manufacturer PAP first. Applications for Lilly Cares, NovoCare, and Sanofi Patient Connection are available online and require income documentation, a prescriber signature, and proof of insurance status. Processing takes 2 to 4 weeks. For immediate needs, Walmart's $25 OTC human insulin (Novolin R, N, or 70/30) provides a bridge, with the understanding that human insulins have slower onset and longer duration than analogs and may require meal-timing adjustments.

Run a GoodRx search for the specific insulin name, concentration, and vial size at pharmacies within 10 miles. Compare the GoodRx price to the manufacturer's own copay card price, as they cannot be combined. The GoodRx research on pharmacy price variation showed a nearly 3-fold price variation for the same insulin at pharmacies within the same zip code.

For CGMs, check whether the device qualifies as DME under Medicare or the commercial plan, request a letter-of-medical-necessity template from the device manufacturer's patient services line, and apply for the manufacturer's own PAP or trial program simultaneously. Dexcom's ACCESS program and Abbott's myFreeStyle program can be initiated by the prescribing clinician at the point of ordering.

Patients in 340B-covered health centers (federally qualified health centers, Ryan White clinics, and certain safety-net hospitals) may access insulin and CGM supplies at 340B acquisition prices, which are substantially below commercial prices. HRSA's 340B program overview lists covered entity types and eligibility criteria.